Format

Send to

Choose Destination
See comment in PubMed Commons below
Schizophr Bull. 2012 Sep;38(5):936-41. doi: 10.1093/schbul/sbs012. Epub 2012 Feb 23.

D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.

Author information

1
Nathan Kline Psychiatric Research Institute and New York University Langone Medical Center, New York, NY, USA. dgoff@nki.rfmh.org

Abstract

As a partial agonist at the glycine site of the NMDA receptor, D-cycloserine (DCS) has been viewed as lacking potency to fully test the NMDA receptor hypofunction theory of schizophrenia. However, findings of full agonist activity at a subset of NMDA receptors that may have particular relevance to schizophrenia, plus a growing body of evidence demonstrating enhancement of learning and neuroplasticity in animal models, suggest novel therapeutic strategies with DCS in schizophrenia. Preliminary studies with once-weekly administration have supported this potential new role for DCS in schizophrenia by demonstrating benefit for negative symptoms, memory consolidation, and facilitation of cognitive behavioral therapy for delusions.

PMID:
22368237
PMCID:
PMC3446239
DOI:
10.1093/schbul/sbs012
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center